How Many People Use GLP-1: Summary Answer
Millions of people worldwide use GLP-1 agonists, with user numbers rising rapidly as these medications gain regulatory approvals and expanded indications. In the United States, recent estimates suggest more than 20 million adults use a GLP-1 receptor agonist, comprising over 10 percent of adults prescribed any diabetes medication. The sharp increase reflects widespread adoption not only for type 2 diabetes and obesity but also for off-label uses and newer approvals for chronic weight management. Growth is driven by clinical evidence, payer coverage decisions, and public awareness, though uptake varies by region, insurance status, and clinical guidelines.
What Are GLP-1 Agonists
GLP-1 agonists are a class of medications that mimic the action of glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. Originally developed to treat type 2 diabetes, these drugs enhance insulin secretion, suppress glucagon release, and slow gastric emptying. More recently, higher doses and specialized formulations have been approved for weight management in people with obesity or overweight conditions. Commonly used GLP-1 agonists include semaglutide, liraglutide, dulaglutide, and tirzepatide, which combines GLP-1 and GIP pathways.
Key Sources and Methods for Estimating Use
Estimates of GLP-1 users draw from multiple sources, including national prescription data, health insurance claims, registries, and surveys. In the United States, sources such as the Centers for Disease Control and Prevention (CDC), the IQVIA Real-World Data (RWD) program, and pharmacy benefit managers provide insights into prescribing and utilization patterns. Agencies in other countries, such as the National Health Service (NHS) in the United Kingdom and the Canadian Institute for Health Information (CIHI), publish comparable data. Because definitions and time frames vary, point estimates should be interpreted as ranges rather than precise counts.
U.S. Prescription-Based Estimates
Large prescription claims datasets help quantify the number of people filling GLP-1 medications. These datasets capture both retail and mail-order pharmacy fills across public and private payers. Analysts use these data to calculate prevalence rates relative to the adult population or specific subpopulations such as those with diabetes or obesity. Adjustments for age, sex, geography, and plan type reduce bias, though undercoverage of certain populations can persist.
Global and Regional Perspectives
Outside the United States, health systems report varying levels of GLP-1 use based on reimbursement policies and guideline recommendations. In Europe and parts of Asia, national health technology assessment bodies have expanded coverage for specific indications, influencing adoption. Multi-country studies often rely on hospitalization and outpatient databases, which can underestimate use in primary care settings. Standardizing measurement across borders remains challenging due to differences in coding, drug availability, and prescribing practices.
How Many People Use GLP-1: Verified Estimates and Trends
Available data suggest that global and national use of GLP-1 agonists has increased markedly over the past several years. Verified estimates vary by source and methodology, but consistent patterns emerge: users are more common in settings with broader insurance coverage and guideline adoption. The rise is especially pronounced among adults with obesity and related cardiometabolic conditions. The following table summarizes key metrics and time periods most relevant to current understanding.
| Metric | Estimate or Range | Source Type and Period |
|---|---|---|
| U.S. Adults Using GLP-1 Agonists (2023–2024) | Over 20 million | Claims and prescription data analyses; IQVIA and CDC-related estimates |
| Prevalence Among U.S. Adults with Diabetes | Over 10 percent of adults using any diabetes medication | Claims-based studies and national surveys |
| Growth Trajectory (Recent Years) | Double-digit annual increase in prescriptions and fills | Pharmacy benefit manager and retail pharmacy data |
| User Demographics | Higher use among adults aged 18–64, insured adults, females in some cohorts | Large health system and national insurance datasets |
Demographics and User Characteristics
GLP-1 users tend to be adults with obesity or overweight, often with comorbidities such as type 2 diabetes, hypertension, or dyslipidemia. In many health systems, users are more frequently female and aged 18 to 64, reflecting both biological factors and differences in utilization patterns. Younger adults may seek these medications for weight-related concerns, while older adults often use them for diabetes management. Access varies by insurance type, with higher utilization in populations with comprehensive pharmacy benefits.
Drivers of Adoption
Several factors have accelerated GLP-1 adoption. Clinical trials and real-world evidence demonstrate meaningful reductions in hemoglobin A1c, body weight, and cardiovascular risk markers. Payer coverage expansions, including coverage of FDA-approved obesity medications, have reduced out-of-pocket costs. Public awareness campaigns and high-profile endorsements have also increased interest. Guideline updates from professional societies have reinforced the role of GLP-1 agonists in diabetes and weight management pathways.
Barriers and Geographic Variation
Despite growth, utilization gaps remain. High drug prices and prior authorization requirements can limit access for some insured individuals. Shortages of certain GLP-1 formulations have periodically constrained supply. Rural areas and lower-income regions may have fewer prescribing clinicians, leading to geographic disparities. Additionally, off-label use, while common, may not be captured in prescription-based estimates, suggesting that true user numbers could be higher than reported.
Practical Considerations for Patients and Providers
Patients considering a GLP-1 agonist should review eligibility criteria, potential benefits, and risks with their clinician. Providers can optimize use by applying current guideline recommendations, monitoring response, and addressing adherence barriers such as cost and side effects. Health systems can improve measurement by tracking filled prescriptions, continuity of use, and clinical outcomes, which supports better resource allocation and patient counseling.
Frequently Asked Questions
- How many people use GLP-1 agonists in the United States? Estimates indicate over 20 million adults use GLP-1 agonists, representing more than 10 percent of adults using any diabetes medication.
- Is use increasing over time? Yes, prescriptions and fills have shown double-digit annual growth in recent years.
- Which demographics use GLP-1 agonists most often? Use is highest among adults aged 18–64, females in some datasets, and populations with comprehensive pharmacy benefits.
- Are global numbers available? Many countries report rising use, but data quality and coverage vary; exact global counts are difficult to standardize.
- Do estimates include off-label use? Most prescription-based estimates include only labeled indications; off-label use may increase total user numbers but is often underrepresented in official data.
Definitions and Context
- GLP-1 agonists: Medications that activate glucagon-like peptide-1 receptors to lower blood sugar and reduce appetite.
- User: An individual who has filled at least one prescription for a GLP-1 agonist within a defined period.
- Prevalence: The proportion of a population using GLP-1 agonists at a given time, often expressed as a percentage.
- Off-label use: Prescribing medications for conditions or doses not explicitly approved by regulatory authorities.
- Prior authorization: A managed care requirement that a prescribing clinician obtain approval before a drug will be covered.